Medexus Pharmaceuticals Inc.

For fiscal Q1 2027, Medexus reported net revenue of $28.6 million, up from $24.6 million in the prior-year quarter. Gross profit was $15.9 million versus $13.8 million last year; gross margin was 55.6% versus 56.0%, and adjusted gross margin was 63.8% versus 65.5%. Adjusted EBITDA increased to $4.7 million from $3.4 million, while net income was $0.5 million, consistent with the prior year, and operating income improved to $2.1 million from $0.9 million. GRAFAPEX product-level net revenue was $4.9 million, with underlying patient demand of $4.8 million, up 23% sequentially from $3.9 million and 118% year over year from $2.2 million. Cash used by operating activities was $0.7 million, net debt was $20.9 million as of June 30, 2026, and net debt to adjusted EBITDA was 1.18x. Management reiterated fiscal 2027 GRAFAPEX product-level net revenue guidance of $30 million to $32 million and said it expects meaningful operating cash flow for the year.

Ken d'Entremont struck an upbeat tone and framed GRAFAPEX as the main growth engine, saying the product had its strongest quarter to date and is increasingly important to Medexus' operating and financial performance. He emphasized repeat hospital ordering, broadening adoption in adult patients, strong pricing, and encouraging payer and access trends. He also highlighted strategy beyond GRAFAPEX, pointing to UM171 in Canada as a good fit with Trecondyv and reaffirming a focus on business development in allo-HSCT and adjacent areas.

Brendon Buschman focused on the quarter's operating leverage and the durability of the existing portfolio. He highlighted that GRAFAPEX product-level net revenue of $4.9 million exceeded $3.2 million of personnel and infrastructure investment, contributing to the $4.7 million adjusted EBITDA result; he also noted the year-over-year EBITDA improvement was partly offset by the absence of a one-time royalty benefit in the prior-year quarter. He said cash used in operations was $0.7 million due mainly to settlement of year-end payables and working-capital timing, and he pointed to net debt of $20.9 million and a 1.18x net debt to adjusted EBITDA ratio while saying the company expects meaningful operating cash flow in fiscal 2027.

Analysts focused mainly on the path from GRAFAPEX's $4.9 million quarterly run rate to the $30 million to $32 million full-year target, with management pointing to formulary listings, payer support, first hospital use, and strong summer uptake as the key leading indicators. Questions also centered on repeat ordering, adult penetration, inventory levels, Rupall post-genericization, IXINITY durability, tariffs, and the UM171 timeline. Management said most GRAFAPEX revenue is now from repeat orders, adult demand is driving growth, wholesaler inventory is roughly one month, Rupall volume has stabilized at a lower level though still slowly declining, IXINITY had a strong quarter partly due to patient-order timing, tariffs are not expected to be material to margins, and a Health Canada meeting on UM171 is expected in the fall.